- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05109117
Clinical Study to Evaluate the Efficacy of an Over-the-counter (OTC) Sunscreen Lip Balm Product
October 5, 2023 updated by: HALEON
A Clinical Study to Evaluate the 8-Hour Moisturization Efficacy of an Over-The-Counter Sunscreen Lip Balm After a Single Application
The purpose of this study is to evaluate the 8-hour moisturization efficacy of OTC sunscreen lip balm after a single treatment application.
Study Overview
Detailed Description
A single-center, randomized, controlled, intra-individual comparison, open label clinical study to determine the 8-hour moisturization efficacy of a sunscreen lip balm.
Skin hydration will be assessed before (Baseline) and after (2, 4, 6 and 8 hours post-treatment) a single treatment with test product, compared to 'no treatment' as control, using a corneometer.
Study treatments will be randomly assigned to 2 test sites delineated on the skin of the participant's volar forearms (one test site on each arm).
A 1-week conditioning phase will precede the test day, during which participants will use the soap provided for personal washing.
Study Type
Interventional
Enrollment (Actual)
39
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
Piscataway, New Jersey, United States, 08854
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Participant must provide a signed and dated, legally effective, informed consent document, which indicates they have been informed of, and understand, all pertinent aspects of the study, before any study procedures are performed (in conformance with 21 Code of Federal Regulations [CFR] Part 50: 'Protection of Human Subjects.')
- Participant must provide relevant details of their medical history and current/recent medications and treatments.
- Participant has completed a Health Insurance Portability and Accountability Act (HIPAA) Authorization Form in conformance with 45 CFR Parts 160 and 164.
- Participant must have completed a Photo Release Form.
- Participant must be able to read, write, speak and understand English.
- Participant must be in good general health.
- Participant must have a valid form of personal identification (photo identity [ID], driver's license, passport, permanent resident card, military ID card; forms cannot be expired)
- Male and female participants of child-bearing potential must agree to use a highly effective method of contraception for the duration of the study and for 14 days after treatment application. (Note: A participant is considered to be of child-bearing potential if, in the opinion of the Principle investigator [PI], they are biologically capable of having children and sexually active.
- Participant must agree to be sequestered in a temperature/humidity monitored test room at the clinical site (temperature 21 degree Celsius [C] +/- 2 degree C, relative humidity [RH] 50 percent [%] +/- 10%) for the duration of the test day (Visit 2), approximately 9.5 hours.
- Participant must agree to bring their own food (dry) and beverages to be consumed on the test day (Visit 2).
- Participant must agree not to consume hot or very cold food/beverages on the test day (Visit 2).
- Participant must agree to use the non-moisturizing soap provided for all personal washing during the conditioning phase of the study.
- Participant must agree to wear loose clothing for ease of access to the test sites (arms) and/or sleeves that can be easily rolled up.
- Participant must agree not to introduce any new cosmetic/toiletry products into their personal care regimen during the study.
- Participant must agree to refrain from any physical effort which might result in thermal regulation by sweating (for example, exercise class, rapid climbing of flights of stairs, jogging, cycling, brisk walking) for at least 2 hours prior to arriving the test day (Visit 2).
- Participant must agree to refrain from prolonged or excessive ultraviolet (UV) exposure (for example, sunbathing, tanning beds) for the duration of the study.
- Participant should be dependable and able to follow directions as outlined in the protocol and Informed Consent Form (ICF).
Exclusion Criteria:
- Participant with scheduled or planned Covid-19 vaccination during likely dates of study participation.
- Female participant who is pregnant, planning to become pregnant during the study, or breastfeeding ( self-reported).
- Participant with a history of sensitivity to any ingredient of the test material or skin marker pen, or latex; or any known sensitivities/allergies, including but not limited to cosmetic/toiletry products and topically applied skin treatment products/drugs.
- Participant with a history of an acute or chronic dermatologic, medical and/or physical condition that would, in the opinion of the investigator, confound study outcomes or increase the risk associated with participation. (Note: dry skin is not an exclusion per se; however, a participant with a level of dryness on the skin of the volar forearms that would, in the opinion of the investigator, confound study outcomes or increase the risk associated with participation should be excluded.
- Participant with a history of skin cancer, or currently undergoing treatment for active cancer of any kind.
- Participant with diabetes.
- Participant with a planned medical treatment/vaccination (other than the Covid-19 vaccination) during the study that would, in the opinion of the investigator, confound study outcomes or increase the risk associated with participation.
- Participant with a planned hospitalization during the study.
- Participant who is currently using, or has used in the past week, any systemic or topical corticosteroid, non-steroid anti-inflammatory drug, antihistamine, sympathomimetic, and/or vasoconstrictor or any other medication that would, in the opinion of the investigator, confound study outcomes or increase the risk associated with participation.
- Participant who is unwilling to cease use of personal care products (for example, moisturizers, lotions, sunscreens, sunless tanners) and/or topical medications at the test sites for the duration of the study.
- Participant who has had extensive UV exposure within 3 weeks of Screening (Visit 1).
- Participant with visual signs of irritation, sunburn, rashes, scratches, burn marks, scarring at the test sites that would interfere with corneometry measurements.
- Participant with excessive hair at the test sites that would interfere with corneometry measurements.
- Participant who has participated in a study involving the arms as a test site, or any other type of clinical study, within three weeks of screening (Visit 1).
- Participant who is an employee/contractor or immediate family member of the PI, study site or Sponsor.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control Arm
No treatment will be applied to the assigned control site.
|
|
Experimental: Test Arm
Single topical application: 80 +/- 2 milligrams (mg) (2.0 +/- 0.05 mg/centimeter^2) of ChapStick Active Performance (CAP) Unscented will be applied to the assigned test site using a fingercot.
The test product will be evenly spread over the test site using light pressure.
|
Sunscreen lip balm.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change From Baseline in Corneometer Measurements
Time Frame: Baseline (pre-treatment), 2, 4, 6 and 8 hours post-treatment
|
Corneometry is an instrumental technique.
It uses a capacitance sensor to measure the dielectric constant of the stratum corneum which is directly proportional to the water content of the skin (skin hydration).
Capacitance of the skin surface is expressed in arbitrary units of skin hydration; the higher value, the more hydrated (moist) the skin.
The mean of 3 corneometer readings taken for each test site at each assessment timepoint (Baseline and 2, 4, 6 and 8 hours post-treatment) was calculated for each individual participant.
Change from Baseline was calculated at each post-treatment timepoint as the post-treatment value minus the Baseline value.
|
Baseline (pre-treatment), 2, 4, 6 and 8 hours post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Improved Corneometer Measurement
Time Frame: 2, 4, 6 and 8 hours post-treatment
|
Percentage of participants with improved corneometer measurement was calculated at each post-treatment timepoint as the number of participants who exhibited improvement (positive change) divided by the total number of participants included in the analysis.
|
2, 4, 6 and 8 hours post-treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 7, 2021
Primary Completion (Actual)
December 17, 2021
Study Completion (Actual)
December 17, 2021
Study Registration Dates
First Submitted
October 26, 2021
First Submitted That Met QC Criteria
October 26, 2021
First Posted (Actual)
November 5, 2021
Study Record Updates
Last Update Posted (Estimated)
March 29, 2024
Last Update Submitted That Met QC Criteria
October 5, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- 218006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
IPD for this study will be made available via the Clinical Study Data Request site.
IPD Sharing Time Frame
IPD will be made available within 6 months of publishing the results of the primary endpoint and safety data of the study.
IPD Sharing Access Criteria
Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place.
Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sunscreening Agents
-
HALEONCompletedSunscreening AgentsUnited States
-
BayerTerminated
-
BayerCompletedSunscreening AgentsUnited States
-
HALEONCompletedSunscreening AgentsUnited States
Clinical Trials on CAP Unscented
-
HALEONCompletedSunscreening AgentsUnited States
-
HALEONCompletedSunscreening AgentsUnited States
-
3MEurotrials Brasil Consultores Cientificos LtdaCompleted
-
Medical University of South CarolinaCompletedMedication AdherenceUnited States
-
Baptist Health South FloridaCompletedOccupational Exposure to RadiationUnited States
-
Washington University School of MedicineTerminatedObscure Gastrointestinal BleedingUnited States
-
Technical University of MunichCompletedVisualisation and Evaluation of Ampulla of VaterGermany
-
Barretos Cancer HospitalUnknownAmpulla of Vater Intestinal-Type AdenomaBrazil
-
Mayo ClinicCompletedEncephalopathy | Altered Mental Status | Nonconvulsive Status Epilepticus | Subclinical Seizure | Nonepileptic SeizuresUnited States
-
Baylor College of MedicineAlliance for Academic Internal MedicineCompletedEndoscopy, GastrointestinalUnited States